Search

Displaying results 4551 - 4560 of 9132 in total
  1. Drug

    Cilomilast

    go.drugbank.com/drugs/DB03849
    Investigational

    It is orally active and acts as a selective Phosphodiesterase-4 inhibitor. … Cilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

  2. Drug

    Brolucizumab

    go.drugbank.com/drugs/DB14864
    ApprovedInvestigational

    Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

  3. Drug

    RR001

    go.drugbank.com/drugs/DB17369
    Investigational

    (AD-PC sTRAIL). … RR001 is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand

  4. Drug

    Inetetamab

    go.drugbank.com/drugs/DB17457
    Investigational

    Inetetamab is a trastuzumab analog. It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

  5. Drug

    Clevidipine

    go.drugbank.com/drugs/DB04920
    ApprovedInvestigational

    Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

  6. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … with a possible increased risk of death outweighing the benefits.

  7. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid … the RNAi response against a targeted disease causing gene.

  8. Drug

    Riferminogene pecaplasmid

    go.drugbank.com/drugs/DB06394
    Investigational

    Riferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.

  9. Drug

    Human Embryonic Stem Cell-derived M Cell

    go.drugbank.com/drugs/DB15734
    Investigational

    CAStem is composed of immunity- and matrix-regulatory cells (IMRCs), also known as M cells, which can be administered through injection. … However, the difference comes with IMRCs displaying a higher quality of consistency, having stronger immunomodulatory and anti-fibrotic functions, and being stronger in potential treatment of lung injury

    Synonyms: M cells
  10. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).